Hi, FL. NVS’ success with Afinitor is in neuroendocrine tumors rather than pancreatic cancer generally. This is a very small market, so it won’t move the needle for a company as large as NVS. Still, Afinitor is an amazing drug when you consider the array of things it does.
The full dataset will be reported as the ESMO conference in October.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.